XTLB XTL Biopharmaceuticals ADRs

XTL Biopharmaceuticals Ltd is engaged in the acquisition & development of pharmaceutical drugs for the treatment of unmet medical needs, currently for the treatment of schizophrenia and Hepatitis C. It has also developed a home therapeutic device. This is an ADR of a company whose stock trades outside of the U.S. as the symbol IT:XTLB.

$3.40
As of 06/23/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Israel
Country of incorporation:  Israel
IPO date:  02/18/2014
Outstanding shares:  5,281,561
Average volume:  12,066
Market cap:   $17,587,598
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    98386D307
ISIN:        US98386D3070
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.10
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy